| Literature DB >> 22706308 |
Jeremy S Tilstra1, Andria R Robinson, Jin Wang, Siobhán Q Gregg, Cheryl L Clauson, Daniel P Reay, Luigi A Nasto, Claudette M St Croix, Arvydas Usas, Nam Vo, Johnny Huard, Paula R Clemens, Donna B Stolz, Denis C Guttridge, Simon C Watkins, George A Garinis, Yinsheng Wang, Laura J Niedernhofer, Paul D Robbins.
Abstract
The accumulation of cellular damage, including DNA damage, is thought to contribute to aging-related degenerative changes, but how damage drives aging is unknown. XFE progeroid syndrome is a disease of accelerated aging caused by a defect in DNA repair. NF-κB, a transcription factor activated by cellular damage and stress, has increased activity with aging and aging-related chronic diseases. To determine whether NF-κB drives aging in response to the accumulation of spontaneous, endogenous DNA damage, we measured the activation of NF-κB in WT and progeroid model mice. As both WT and progeroid mice aged, NF-κB was activated stochastically in a variety of cell types. Genetic depletion of one allele of the p65 subunit of NF-κB or treatment with a pharmacological inhibitor of the NF-κB-activating kinase, IKK, delayed the age-related symptoms and pathologies of progeroid mice. Additionally, inhibition of NF-κB reduced oxidative DNA damage and stress and delayed cellular senescence. These results indicate that the mechanism by which DNA damage drives aging is due in part to NF-κB activation. IKK/NF-κB inhibitors are sufficient to attenuate this damage and could provide clinical benefit for degenerative changes associated with accelerated aging disorders and normal aging.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22706308 PMCID: PMC3386805 DOI: 10.1172/JCI45785
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808